Clinical Trial Update: A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and tolerability of assisted and self-administered subcutaneous trastuzumab as adjuvant therapy in early HER2-positive breast ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Neoplasms

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2017-04-18